Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCEL vs RAPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCEL Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

VCEL Overall Winner 6-Pillar Tally: VCEL 6 – 0 RAPT Matrix Metrics: VCEL 7 – 3 RAPT

As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCEL carries a Unified Composite Score of 34.8/100 (SELL) at $57.68 (60.5x Forward P/E, 8.3% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. VCEL 34.8/100 SELL), VCEL captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.3% vs. 0.0% operating margin) and revenue trajectory (+26.5% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCEL vs RAPT
VCEL NASDAQ Head-to-Head Winner
Vericel Corporation
Biological Products, (No Disgnostic Substances)
$57.68
+1.26% 1D
Market Cap $2.9B
TTM Revenue $324M
Forward P/E 60.5x
Beta / 30D Vol 0.31β · 75% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 50.0 Fund 34.0 Flow 70.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 74
RSI-14: 73.9 · SMA20: $47.98 · SMA50: $43.13
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67

6-Pillar Scorecard Institutional Category Breakdown (VCEL 6 – 0 RAPT)

Columns: Metric · VCEL · RAPT
1. Valuation Multiples VCEL
Forward P/E 60.5x N/M
Trailing P/E 90.3x N/M
PEG Ratio N/M N/M
EV / Revenue 9.0x N/M
2. Growth & Scale VCEL
Revenue Growth (YoY) +26.5% -100.0%
Earnings Growth (YoY) +170.0% +0.0%
TTM Revenue (USD) $324M N/A
Market Cap $2.9B $1.7B
3. Profitability & Quality VCEL
Gross Margin 74.5% N/A
Operating Margin 8.3% 0.0%
Net Profit Margin 10.3% 0.0%
Return on Equity (ROE) 9.4% -85.4%
4. Balance Sheet & Cash Flow VCEL
Cash Generation (TTM) $58M N/A
Cash Flow Margin 17.9% N/A
Net Cash / Leverage $43M Net Cash $9.02 Book/Sh · -85.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCEL
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 44.1% (13th %ile) 0.8% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat VCEL
OpEx & R&D Intensity 66.2% of Rev ($215M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCEL (7) vs RAPT (3)
Institutional Metric VCEL RAPT Criterion Row Edge
Market Capitalization
Scale
$2.9B $1.7B Larger Scale VCEL
Trailing P/E Ratio
Valuation
90.3x N/M Lower Multiple VCEL
Forward P/E Ratio
Valuation
60.5x N/M Lower Multiple VCEL
Revenue Growth (YoY)
Growth
+26.5% -100.0% Higher Growth VCEL
Operating Margin (TTM)
Profitability
8.3% 0.0% Higher Margin VCEL
Net Profit Margin
Profitability
10.3% 0.0% Higher Margin VCEL
Return on Equity (ROE)
Capital Efficiency
9.4% -85.4% Higher ROE VCEL
52-Week Range Position
Momentum
93% ($29–$60) 100% ($1–$58) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
0.31β · 75% Vol -0.02β · 2% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
34.8 / 100 (SELL) 52.4 / 100 (HOLD) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
$324M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$58M ($43M Net Cash) N/A ($9.02 Book/Sh · -85.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPT +3.8 pp
VCEL: -3.12% · RAPT: +0.68%
3M Horizon RAPT +86.85 pp
VCEL: -12.41% · RAPT: +74.44%
6M Horizon RAPT +113.24 pp
VCEL: -11.29% · RAPT: +101.95%
1Y Horizon RAPT +113.24 pp
VCEL: -11.29% · RAPT: +101.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VCEL vs RAPT. Trailing 12-month operating profitability (VCEL 8.3% vs RAPT 0.0%) and valuation multiples (VCEL 60.5x vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VCEL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$324M
Gross Margin74.5%
Op. Margin8.3%
ROE / Fwd P/E9.4% · 60.5x
RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCEL SURGE
5d in phase · OBV ACCUMULATION
Current IV 44.1%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact VCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCEL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($215M)
90D Engineering Disclosures 0 Published
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VCEL vs RAPT Key Questions & Quantitative Answers

As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCEL carries a Unified Composite Score of 34.8/100 (SELL) at $57.68 (60.5x Forward P/E, 8.3% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. VCEL 34.8/100 SELL), VCEL captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.3% vs. 0.0% operating margin) and revenue trajectory (+26.5% vs. -100.0% YoY).

VCEL leads the Growth & Scale pillar: VCEL posts +26.5% YoY revenue growth and +170.0% YoY earnings growth on $324M TTM revenue (74.5% gross margin, 8.3% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VCEL generates $324M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, VCEL deploys 66.2% of Rev ($215M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.

VCEL screens cheaper on headline valuation multiples. VCEL trades at 60.5x Forward P/E, 90.3x Trailing P/E, N/M PEG, and 9.0x EV/Revenue (17.9% FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCEL (9.4% ROE) versus RAPT (-85.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VCEL carries 44.1% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.31β · 75% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.